About ENCUE INC.
ENCUE is a Northwestern spinout focused on developing novel therapeutics for neurodegenerative and neuropsychiatric disorders through proprietary platform technology that creates synthetic, orally deliverable receptor modulators. The company has six molecules in Phase 2/3 clinical trials.
Development of novel receptor modulators for neurodegenerative and psychiatric disordersProprietary platform technology for creating synthetic, orally deliverable therapeuticsFocus on restoring synaptic function and neuroplasticity associated with learning and memory
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to ENCUE INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.